

Diese Meldung kann unter <http://www.presseportal.de/pm/64962/1192260/eisai-s-commitment-to-oncology-demonstrated-by-clinical-data-to-be-presented-at-asco-annual-meeting> abgerufen werden.

Eisai Europe Limited

Eisai's Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting

16.05.2008 - 08:15 Uhr, Eisai Europe Limited

London (ots/PRNewswire) - Eisai Europe Ltd announced today that results from 9 clinical data abstracts about compounds in the company's oncology pipeline, product portfolio and preclinical oncology research have been accepted for presentation at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago from May 30 to June 3, 2008.

A wide variety of abstracts on Eisai investigational compounds will showcase research focused on metastatic breast cancer, lung cancer, ovarian cancer, mesothelioma, pancreatic cancer and other types of cancer, as well as supportive care to aid those currently undergoing treatment for cancer.

"Eisai's commitment to oncology is clearly translating into the substantial growth of our pipeline," said Haruo Naito, President and CEO, Eisai Co., Ltd. "Eisai's focus on becoming a global leader in oncology reflects our human health care mission to satisfy unmet medical needs and increase benefits to patients and their families."

The following Eisai abstracts are accepted for presentation at this year's ASCO meeting.

Product	Abstract Details	Location Details
MORAb-003 (farletuzumab)	Exploratory Phase II Efficacy Study of MORAb-003, a Monoclonal Antibody against Folate Receptor Alpha, in Platinum-Sensitive Ovarian Cancer in First Relapse	June 1, 2008 4:30-4:45 p.m.
Abstract No: 5500	Oral Presentation	Location: S406 (Vista Room)
E7080	A phase I study of E7080 in patients with advanced malignancies	May 31, 2008 8:00 a.m.-12:00 p.m.
Abstract No: 3526	Poster 3 Awarded a Foundation Merit Award	Location: W375E Lobby Poster discussion 12:00-1:00 p.m.
E7080	Phase I dose escalation study and biomarker analysis of E7080 in patients with advanced solid tumors	May 31, 2008 8:00 a.m.-12:00 p.m.
Abstract No: 3527	Poster 4	Location: W375E Lobby Poster discussion 12:00-1:00 p.m.
MORAb-003 (farletuzumab)	A Phase I Study of MORAb-003, a Humanized Monoclonal Antibody Against Folate Receptor Alpha, in Advanced Epithelial Ovarian Cancer	May 31, 2008 2:00-6:00 p.m.
Abstract No: 5517	Poster 7	Location: S403 Poster discussion

		5:00-6:00 p.m. Location: S406 (Vista Room) May 31, 2008
GCP II Inhibitor	Glutamate Carboxypeptidase II Inhibition in Rat Models of Chemotherapy-induced Peripheral Neurotoxicity	2:00-6:00 p.m.
Abstract No: 9558	Poster 37A	Location: S Hall A1 June 1, 2008
E7820	A phase I study of E7820 in combination with cetuximab in patients (pts) with advanced solid tumors	2:00-6:00 p.m.
Abstract No: 3568	Poster 24G	Location: S Hall A1 June 1, 2008
MORAb-009	A Phase I Study of MORAb-009, a Monoclonal Antibody against Mesothelin, in Mesothelioma, Pancreatic, and Ovarian Cancer	2:00-6:00 p.m.
Abstract No: 3578	Poster 27C	Location: S Hall A1 June 2, 2008
Eribulin Mesylate (E7389)	Phase II Study of Eribulin Mesylate (E7389) in Patients with Locally Advanced or Metastatic Breast Cancer	2:00-6:00 p.m.
Abstract No: 1084	Previously Treated with Anthracycline, Taxane, and Capecitabine Therapy Poster 38A	Location: S Hall A1
Advanced Breast Cancer	Oncologist and Patient Roles in Assessing Current and Future Treatment for Metastatic Breast Cancer: Results of an Observational Linguistic study Poster 32B	June 2, 2008 2:00-6:00 p.m. Location: S Hall A1
Abstract No: 1064		Eisai began its

oncology research program in 1987, discovering several small molecules that are in development as chemotherapeutic agents. In addition to its in-house oncology research and development (R&D) program, Eisai made three strategic acquisitions to establish a solid business infrastructure and enter the oncology market.

In October 2006, Eisai acquired four products mainly for the treatment of cutaneous T-cell lymphoma, as well as an oncology specialty sales force from Ligand Pharmaceuticals. This provided Eisai with an initial commercial infrastructure for oncology products. The acquisition of Morphotek, Inc. in April 2007 added important antibody technology and an antibody pipeline. In January 2008, Eisai acquired MGI PHARMA, INC., an oncology and acute care-focused company, to broaden its R&D and commercial capabilities, pipeline and product portfolio in oncology and supportive care.

Eisai is committed to addressing the unmet medical needs of patients with cancer and to delivering novel treatment options that create hope.

Note to Editors

About Eisai Europe Ltd.

Established in 1989, Eisai Europe Ltd. is the European pharmaceutical subsidiary of Eisai Co. Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide health care system. Eisai focuses its efforts in two main therapeutic areas; integrative neurology and integrative oncology/critical care. Eisai employs more than 9,500 people worldwide.

Contact:

For further information please contact: Andrew Day, Communications
Director, Eisai Europe Ltd, +44(0)208-600-1400, +44(0)7973-411-419

Originaltext:

Eisai Europe Limited

Pressemappe:

<http://www.presseportal.de/pm/64962/eisai-europe-limited>

Pressemappe als RSS:

http://presseportal.de/rss/pm_64962.rss2